OXYTOCIN ANTIBODIES (BRD)

This is an antibody preparation generated in rabbit by Dr. William North Professor of Physiology and Neurobiology of Dartmouth Medical School (now Geisel  Medical  School at Dartmouth) using oxytocin coupled to bovine thyroglobulin. 

Specificity:  Less than 0.1% cross-reactivity with vasopressin, and less than 0.5% with vasotocin,  in RIA 

Tested Applications IHC-formaldehyde fixed tissues, Flow cytometry, , RIA, ELISA 

Properties 

Form: Liquid 

Storage Instructions Shipped at 4o C. Store at 4o C short term (1-2 weeks). Upon delivery                                             aliquot and store at -20o C or -80o C. Avoid freeze/Thaw cycling. 

Storage buffer:         Preservative none -Stable if stored as 1:100 dilutions in PBS containing 1.25 mg/ml of BSA at -20o C. Constituents: Whole serum 

Purity:                         Whole Antiserum 

Clonality:                 Polyclonal 

Isotype:                     IgG, Behaves chromatographically like mouse IgG2B 

Research Areas:         Neuroscience, Endocrinology, Neuropeptides, Hormones, Neuroendocrinology, OBGYN, Cancer 

----------------------------------------------------------------------------------

Woomera Therapeutics Inc.  guarantees use of BRG in each of the tested applications: 

The application information recommends certain starting dilutions; however, optimal dilutions/concentrations should be determined by the end user. 

Application

IHC:   Use at an assay dependent concentration 

RIA: 1/30,000-99,000. Sensitivity to 0.2 pg/ml; <0.1% AVP cross-reaction. 

ELISA: 1/30,000-50,000 

Flow Cytometry: 1/1000-5000 

Western :   1/1000-5000 

References 

North, W.G.  Neuropeptide production by small-cell carcinoma:  Vasopressin and oxytocin as plasma markers of disease.  J. Clin. Endocrin. Metab. 73:1316-1320, 1991. 

Cheng, S.W.T., and North, W.G.  Absence of negative feedback by oxytocin on release from magnocellular neurones in conscious rats.  Can. J. Physiol. Pharmacol.  70(1):100-105, 1992. 

North, W.G., Harbaugh, R., and Reeder, T.  An evaluation of human neurophysin production in Alzheimer's disease:  Preliminary observations.  Neurobiol. Aging  13(2):261-265, 1992. 

Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., et al.  The role of central oxytocin in obsessive compulsive disorder and related normal behavior.  Psychoneuroendocrinology  19:723-749, 1994.

Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., Price, L.H., et al.  Elevated CSF levels of oxytocin in obsessive compulsive disorder: comparison with Tourette's syndrome and healthy controls.  Archives of Gener. Psychiatry 51:782-792, 1994. 

Martin, A., State, M., Anderson, G.M., Kaye, W.M., Hanchett, J.M., McConaha, C.W., North, W.G., and Leckman, J.F.  Cerebrospinal Fluid of Oxytocin in Prader-Willi Syndrome: A Preliminary Report.  Soc. Biol. Psych.  44: 1349-1352, 1998. 

Martin, A., State, M., Koenig, K., Schultz, R., Dykens, E.M., Cassidy, S.B., and Leckman, J.F.  Prader-Willi Syndrome.  Am. J. Pysch.  155: 1265-1273, 1998.    

Piqueux, C., Hagelstein M.T., Keegan, B., Legros, V., and North, W.G. Vasopressin and Oxytocin mitogen transduction pathway in small cell lung cancer cells.  Endocr.-Relat. Cancer, 4:871-875, 2004.  

Product Code BRD